Biopharmaceutical Contract Manufacturing Market Size to Reach $115.65 billion by 2034

According to the report, the market is valued at USD 49.44 billion in 2026, which is expected to grow to USD 115.65 billion by 2034. The projected CAGR for this period is 11.21%

The biopharmaceutical contract manufacturing market is segmented based on service, source, drug type, therapeutic area, and region. Some of the insights provided in the report are highlighted below:

The analytical & QC studies segment is expected to be the fastest growing with a CAGR of 11.69% during the forecast period.
North America is expected to lead the biopharmaceutical contract manufacturing market during the forecast period, owing to the strong presence of leading biopharmaceutical companies and the availability of advanced technologies such as digital manufacturing.
Companies are investing in research & development to develop monoclonal antibodies, cell & gene therapies, and vaccines.
Brazil is expected to lead the Latin America biopharmaceutical contract manufacturing market due to local vaccine self-sufficiency initiatives and focus on regulatory approvals.

Straits Research adopts a rigorous 360° research approach that integrates both primary and secondary research methodologies. The report data is triangulated with a mix of market indicators, macroeconomic outlook, industry sources, and strategic briefings.

The report is designed to enable decision makers, such as CXOs, policymakers, investors, startups, and other related stakeholders, to understand the current and future scenario of the market.